Ferroptosis in the tumor immune microenvironment: from danger signals to immune reprogramming
- 1The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology
- 2Department of Hepatobiliary Surgery, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases
- 3The First Affiliated Hospital of Zhengzhou University
Abstract
Immune-checkpoint blockade has changed cancer therapy, yet durable responses remain limited by immune exclusion, myeloid suppression and metabolic adaptation within the tumor immune microenvironment. Ferroptosis, an iron-dependent form of lipid-peroxidation-driven regulated cell death, offers a mechanistic bridge between tumor metabolism and antitumor immunity. Ferroptotic tumor cells can release danger signals, oxidized lipid mediators and antigenic material that shape dendritic-cell activation, macrophage behavior, myeloid-derived suppressor cell function and CD8+ T-cell responses. Based on currently heterogeneous evidence, we propose a working model in which acute and spatially restricted tumor-cell ferroptosis may favor immune priming and checkpoint sensitivity, whereas persistent or broadly distributed lipid-peroxidation stress may impair effector immune cells and sustain suppressive states. This temporal-spatial distinction remains incompletely validated in directly comparable experimental systems. This review summarizes the biochemical foundations of ferroptosis, the immune signals released by ferroptotic cells, the reprogramming of innate and adaptive immune compartments, and the emerging use of ferroptosis inducers, nanomedicines and immune-checkpoint combinations. We also discuss biomarkers, in vivo monitoring and immune-cell-specific toxicity as key barriers to clinical translation. A central conclusion is that ferroptosis should be treated not as a monolithic tumoricidal modality, but as a microenvironment-specific immune remodeling process whose therapeutic value depends on timing, localization and preservation of antitumor immune function.
Related
- Redox Storm in the Tumor Microenvironment (ΤΜΕ): Multifaceted Redox Injury and Immunometabolic Reprogramming Induced by Immune Checkpoint Blockade in B16F10 Melanoma: An Ultrastructural Study of the Peritumoral Interface
- Targeting Dendritic Cells in Cancer Immunotherapy: From Immune Priming to Tumor Microenvironment Reprogramming
- Reprogramming the tumor microenvironment in mesothelioma: from immune suppression to therapeutic opportunity
- Rewiring the breast cancer immune microenvironment through non-coding RNA-macrophage crosstalk: therapeutic vulnerabilities for immune reprogramming
- Integrated pharmacology and validation reveal Formononetin upregulates GSTM2 to modulate prostate cancer immune microenvironment via ROS/STAT3-driven chemokine reprogramming
BibTeX
@article{shi2026ferroptosis,
title = {{Ferroptosis in the tumor immune microenvironment: from danger signals to immune reprogramming}},
author = {Qingmiao Shi and Bingqian Tan and Huiwu Xing},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1978294},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978294/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ferroptosis in the tumor immune microenvironment: from danger signals to immune reprogramming
AU - Qingmiao Shi
AU - Bingqian Tan
AU - Huiwu Xing
PY - 2026
DA - 2026/10/14
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1978294
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1978294/full
AB - Immune-checkpoint blockade has changed cancer therapy, yet durable responses remain limited by immune exclusion, myeloid suppression and metabolic adaptation within the tumor immune microenvironment. Ferroptosis, an iron-dependent form of lipid-peroxidation-driven regulated cell death, offers a mechanistic bridge between tumor metabolism and antitumor immunity. Ferroptotic tumor cells can release danger signals, oxidized lipid mediators and antigenic material that shape dendritic-cell activation, macrophage behavior, myeloid-derived suppressor cell function and CD8+ T-cell responses. Based on currently heterogeneous evidence, we propose a working model in which acute and spatially restricted tumor-cell ferroptosis may favor immune priming and checkpoint sensitivity, whereas persistent or broadly distributed lipid-peroxidation stress may impair effector immune cells and sustain suppressive states. This temporal-spatial distinction remains incompletely validated in directly comparable experimental systems. This review summarizes the biochemical foundations of ferroptosis, the immune signals released by ferroptotic cells, the reprogramming of innate and adaptive immune compartments, and the emerging use of ferroptosis inducers, nanomedicines and immune-checkpoint combinations. We also discuss biomarkers, in vivo monitoring and immune-cell-specific toxicity as key barriers to clinical translation. A central conclusion is that ferroptosis should be treated not as a monolithic tumoricidal modality, but as a microenvironment-specific immune remodeling process whose therapeutic value depends on timing, localization and preservation of antitumor immune function.
SN - 1664-3224
ER -